ARQT Stock Price | Arcutis Biotherapeutics Inc P/E, Revenue, EPS, & Forecasts

Arcutis Biotherapeutics Inc • ARQT

Capital at risk.

About
Metrics
Forecasts
Earnings performance
Financial performance
Sentiment analysis
FAQs

About Arcutis Biotherapeutics Inc

Ticker

ARQT

Trading on

NASDAQ

ISIN

US03969K1088

Industry

Biotechnology

Sector

Healthcare

CEO

Todd Franklin Watanabe M.A.

Headquarters

3027 Townsgate Road, Westlake Village, CA, United States, 91361

Employees

354

Website

arcutis.com

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Metrics

BasicAdvanced

Market cap

$2.76B

P/E ratio

EPS

-$0.13

Dividend Yield

0.00%

Beta

1.74

Forward P/E ratio

123.46

EBIDTA

$-7.6M

Ex dividend date

Price & volume

Market cap

$2.76B

Average daily volume

1.5M

90-day return

30-day return

7-day return

Dividends

Dividend per share

$0.00

Dividend yield

0.00%

Forward dividend per share

$0.00

Forward dividend yield

0.00%

Payout ratio

0.00%

Valuation

P/E ratio

Forward P/E

123.46

PEG ratio

Trailing P/E

Price to sales

7.34

Price to book

14.55

Earnings

EPS

-$0.13

EPS estimate (current quarter)

$0.09

EPS estimate (next quarter)

$0.03

EBITDA

$-7.6M

Revenues (TTM)

$376M

Revenues per share (TTM)

$2.96

Technicals

Beta

1.74

52-week High

$31.77

52-week Low

$11.86

50-day moving average

$25.94

200-day moving average

$21.40

Short ratio

11.65

Short %

15.11%

Management effectiveness

ROE (TTM)

-9.30%

ROA (TTM)

-1.96%

Profit margin

-4.29%

Gross profit margin

$339M

Operating margin

14.20%

Growth

Quarterly earnings growth (YoY)

0.00%

Quarterly revenue growth (YoY)

81.50%

Share stats

Outstanding Shares

124M

Float

91.9M

Insiders %

1.71%

Institutions %

108.55%

Analyst Insights & forecasts

100% Buy

0% Hold

0% Sell

Based on information from 7 analysts.

Average price target

$34.75

Earnings per share (EPS) forecast

windowbar_chart_4_bars

Actual

Expected

Surprise

-$0.20

-$0.73

72.60%

Q1 • 25Beat

-$0.13

-$0.17

23.53%

Q2 • 25Beat

$0.06

-$0.10

159.76%

Q3 • 25Current

QuarterlyAnnual

Financial Performance

windowbar_chart_4_bars

Income StatementBalance SheetCash Flow

windowbar_chart_4_bars

Revenue

Net income

Profit margin

$99.2M

$7.4M

7.47%

Q3 • 25

$130M

$17.4M

13.43%

Q4 • 25

30.52%

134.75%

79.85%

QoQ growth

QuarterlyAnnual

Totals assets

Total liabilities

Debt to assets

$371M

$213M

57.39%

Q3 • 25

$433M

$243M

56.24%

Q4 • 25

16.71%

14.37%

-2.01%

QoQ growth

QuarterlyAnnual

Operating

Investing

Financing

Free cash flow

$-1.8M

$-25.2M

$1.5M

$-1.8M

Q3 • 25

$26.2M

$-34.2M

$3.7M

$26.2M

Q4 • 25

-1,592.87%

35.38%

152.17%

-1,592.87%

QoQ growth

QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Arcutis Biotherapeutics Inc share?

Arcutis Biotherapeutics Inc shares are currently traded for undefined per share.

How many shares does Arcutis Biotherapeutics Inc have?

Arcutis Biotherapeutics Inc currently has 124M shares.

Does Arcutis Biotherapeutics Inc pay dividends?

No, Arcutis Biotherapeutics Inc doesn't pay dividends.

What is Arcutis Biotherapeutics Inc 52 week high?

Arcutis Biotherapeutics Inc 52 week high is $31.77.

What is Arcutis Biotherapeutics Inc 52 week low?

Arcutis Biotherapeutics Inc 52 week low is $11.86.

What is the 200-day moving average of Arcutis Biotherapeutics Inc?

Arcutis Biotherapeutics Inc 200-day moving average is $21.40.

Who is Arcutis Biotherapeutics Inc CEO?

The CEO of Arcutis Biotherapeutics Inc is Todd Franklin Watanabe M.A..

How many employees Arcutis Biotherapeutics Inc has?

Arcutis Biotherapeutics Inc has 354 employees.

What is the market cap of Arcutis Biotherapeutics Inc?

The market cap of Arcutis Biotherapeutics Inc is $2.76B.

What is the P/E of Arcutis Biotherapeutics Inc?

The current P/E of Arcutis Biotherapeutics Inc is null.

What is the EPS of Arcutis Biotherapeutics Inc?

The EPS of Arcutis Biotherapeutics Inc is -$0.13.

What is the PEG Ratio of Arcutis Biotherapeutics Inc?

The PEG Ratio of Arcutis Biotherapeutics Inc is null.

What do analysts say about Arcutis Biotherapeutics Inc?

According to the analysts Arcutis Biotherapeutics Inc is considered a buy.